Criado em 2006 (França), I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome possui 2757 marcas irmãs e 17478 marcas concorrentes. A marca I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome é propriedade de SANOFI, uma empresa listada em Paris. O ISIN, codigo de empresa cotada na bolsa de valores, é FR0000120578. O setor de I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome é Fabricantes de medicamentos.